%0 Journal Article %A Huang, David B. %A Charrier, Cedric %A Le Bras, Chloé %A Hawser, Stephen %A Noviello, Stephanie %T The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections %D 2019 %J Journal of Medical Microbiology, %V 68 %N 6 %P 898-902 %@ 1473-5644 %R https://doi.org/10.1099/jmm.0.000989 %K iclaprim %K resistance %K incidence %K Staphylococcus aureus %K skin infections %I Microbiology Society, %X The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml−1 for S. aureus (0.12 µg ml−1 against methicillin-sensitive and 0.25 µg ml−1 against methicillin-resistant S. aureus ). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml−1 was 2.0  % (16/790). The clinical outcomes varied by MICs for early clinical response (63–100  %), end of therapy response (81–100  %) and the test of cure response (75–100  %). For microbiological outcomes of these infections, the end of therapy response was 80–100  % and the test of cure response was 88–100  %. %U https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000989